A Global Phase 3, Randomized, Open-label, Multi-center TrialDesigned to Compare the Efficacy and Safety of LisocabtageneMaraleucel vs Investigator?s Choice Options (idelalisib + rituximab orbendamustine + rituximab) in Adult Participants with Relapsed

Project: Research project

Project Details

Description

A Global Phase 3, Randomized, Open-label, Multi-center Trial Designed to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator?s Choice Options (idelalisib + rituximab or bendamustine + rituximab) in Adult Participants with Relapsed
StatusActive
Effective start/end date9/5/239/30/33

Funding

  • BRISTOL-MYERS SQUIBB COMPANY

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.